INmune Bio
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2015-01-01
- Employees
- 17
- Market Cap
- -
- Website
- http://www.inmunebio.com
- Introduction
INmune Bio, Inc. Is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprograms the immune system to fight cancer and Alzheimer’s disease. Its products include pipeline, INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate. The company was founded by Mark Lowdell in September 2015 and is headquartered in Boca Raton, FL.
Study of INKmune in Patients With mCRPC (CaRe Prostate)
- Conditions
- Metastatic Castration-resistant Prostate CancerCancermCRPC
- Interventions
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Inmune Bio, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT06056791
- Locations
- 🇺🇸
VA Greater Los Angeles Healthcare System, Los Angeles, California, United States
🇺🇸University of California, Los Angeles, Los Angeles, California, United States
🇺🇸Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML
- Conditions
- CancerMDS-EBAcute Myeloid LeukemiaMyelodysplastic SyndromesAML
- Interventions
- Biological: INKmune
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Inmune Bio, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT05933070
- Locations
- 🇬🇷
Attikon University General Hospital, Athens, Attiki, Greece
🇬🇧Sheffield Teaching Hospitals NHS FT - Royal Hallamshire Hospital, Sheffield, United Kingdom
🇬🇧University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire, United Kingdom
An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease
- Conditions
- Central Nervous System DiseasesTauopathiesMental DisordersAlzheimer DiseaseBrain DiseasesDementiaNeurodegenerative DiseasesNeurocognitive DisordersNervous System Diseases
- Interventions
- First Posted Date
- 2022-08-31
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Inmune Bio, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT05522387
- Locations
- 🇦🇺
Australian Alzheimer's Research Foundation, Perth, Western Australia, Australia
🇦🇺KaRa MINDS, Macquarie Park, New South Wales, Australia
🇦🇺Neuro Trials Victoria Pty Ltd T/A NeuroCentrix, Carlton, Victoria, Australia
Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation
- Conditions
- DementiaMild Cognitive Impairment (MCI)Alzheimer DiseaseBrain DiseasesNervous System DiseasesCentral Nervous System DiseasesTauopathiesNeurodegenerative DiseasesMental Disorders
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-04-11
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Inmune Bio, Inc.
- Registration Number
- NCT05321498
A Study of XPro1595 in Patients with Early Alzheimer's Disease with Biomarkers of Inflammation
- Conditions
- Alzheimer DiseaseDementiaBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesTauopathiesNeurodegenerative DiseasesNeurocognitive DisordersMental DisordersMild Cognitive Impairment
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Inmune Bio, Inc.
- Target Recruit Count
- 201
- Registration Number
- NCT05318976
- Locations
- 🇬🇧
INmune Bio Investigational Site, Winchester, United Kingdom
INB03 for the Treatment of Pulmonary Complications From COVID-19
- First Posted Date
- 2020-04-30
- Last Posted Date
- 2022-03-18
- Lead Sponsor
- Inmune Bio, Inc.
- Target Recruit Count
- 79
- Registration Number
- NCT04370236
- Locations
- 🇺🇸
NEA Baptist, Jonesboro, Arkansas, United States
🇺🇸Mississippi Baptist, Kosciusko, Mississippi, United States
🇺🇸Jewish Hospital, Louisville, Kentucky, United States
A Biomarker-directed Study of XPro1595 in Patients With Alzheimer's
- First Posted Date
- 2019-05-09
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Inmune Bio, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT03943264
- Locations
- 🇦🇺
KaRa MINDS, Macquarie Park, New South Wales, Australia
🇦🇺Central Adelaide Local Health Network, Woodville, South Australia, Australia
🇦🇺Mater Medical Research Institute, Brisbane, Queensland, Australia